NOT.BE : Summary for NOVARTIS NAM. SF 0,50 - Yahoo Finance

U.S. Markets open in 6 hrs 53 mins


Berlin - Berlin Delayed Price. Currency in EUR
Add to watchlist
65.41-0.14 (-0.21%)
As of 2:01 AM EST. Market open.
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close65.55
Bid65.24 x 87300
Ask65.40 x 10000
Day's Range65.41 - 65.41
52 Week Range63.00 - 68.28
Avg. Volume502
Market CapN/A
PE Ratio (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Kiplinger16 hours ago

    7 Stocks for Retirees to Beat the Market in 2017

    Forget politics. Instead, look for reasonably priced companies with competitive advantages.

  • Reuters2 days ago

    Novartis' drug tops chemotherapy in untreated lung cancer patients

    Novartis AG said its cancer drug, Zykadia, was twice as effective as chemotherapy in slowing the progression of a rare form of lung cancer in a late-stage study. Patients with anaplastic lymphoma kinase-positive (ALK+)advanced non-small cell lung cancer treated with Zykadia had a median progression-free survival of 16.6 months, compared to 8.1 months for those on chemotherapy. Novartis' drug also has conditional approval as a second-line treatment in Europe.

  • Reuters2 days ago

    Exclusive: Novartis in talks to sell some central nervous system drugs - sources

    Novartis is in talks about the sale of some older neuroscience drugs, people close to the matter said, as the Swiss drugmaker clears the decks to concentrate on promising new medicines it hopes will help to restore sales growth. Novartis did not immediately return phone calls and emails seeking comment. Chief Executive Joe Jimenez is in the process of refreshing the group's drugs portfolio to help return the company to sales growth.